Still, the use of palbociclib (a CDK4/6 inhibitor) associated with omipalisib (a PI3K/mTOR dual inhibitor) in ATC in vitro and in vivo models significantly reduced cell proliferation in cell lines and inhibited tumor growth in lower doses [67]. This evidence concerns the gene PIK3CA and neoplasm.